Phase II study of sunitinib in patients with metastatic urothelial cancer Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Indoles
  • Neoplasms, Glandular and Epithelial
  • Pyrroles
  • Urinary Bladder Neoplasms

abstract

  • Sunitinib did not achieve the predetermined threshold of >or= 20% activity defined by Response Evaluation Criteria in Solid Tumors. However, antitumor responses were observed, identifying the vascular endothelial growth factor axis as a viable pathway for UC treatment. The reported clinical benefit in previously treated patients warrants further investigation in a disease for which there is no US Food and Drug Administration-approved treatment.

publication date

  • March 10, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2009.25.3922

PubMed ID

  • 20142593

Additional Document Info

start page

  • 1373

end page

  • 9

volume

  • 28

number

  • 8